Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Return on Equity: 2018-2025

Historic Return on Equity for Crinetics Pharmaceuticals (CRNX) over the last 7 years, with Sep 2025 value amounting to -0.38%.

  • Crinetics Pharmaceuticals' Return on Equity fell 5.00% to -0.38% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.38%, marking a year-over-year decrease of 5.00%. This contributed to the annual value of -0.32% for FY2024, which is 17.00% up from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Return on Equity stood at -0.38% for Q3 2025, which was down 23.69% from -0.30% recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Return on Equity ranged from a high of -0.25% in Q1 2025 and a low of -0.69% during Q2 2023.
  • Over the past 3 years, Crinetics Pharmaceuticals' median Return on Equity value was -0.33% (recorded in 2024), while the average stood at -0.39%.
  • Its Return on Equity has fluctuated over the past 5 years, first tumbled by 31bps in 2023, then soared by 39bps in 2024.
  • Quarterly analysis of 5 years shows Crinetics Pharmaceuticals' Return on Equity stood at -0.37% in 2021, then decreased by 12bps to -0.49% in 2022, then grew by 11bps to -0.38% in 2023, then grew by 11bps to -0.28% in 2024, then fell by 5bps to -0.38% in 2025.
  • Its last three reported values are -0.38% in Q3 2025, -0.30% for Q2 2025, and -0.25% during Q1 2025.